Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $139,809.20 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total value of $139,809.20. Following the sale, the insider now owns 247,173 shares in the company, valued at approximately $8,952,606.06. The trade was a 1.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The stock was sold at an average price of $30.48, for a total value of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.

Apogee Therapeutics Stock Performance

APGE stock opened at $32.32 on Friday. Apogee Therapeutics, Inc. has a one year low of $29.10 and a one year high of $63.50. The firm’s fifty day moving average is $37.21 and its 200 day moving average is $45.49. The firm has a market cap of $1.46 billion, a PE ratio of -13.36 and a beta of 1.72.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). Research analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on APGE. Citigroup initiated coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Wedbush reiterated an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $92.17.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Apogee Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock worth $432,000 after buying an additional 892 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Apogee Therapeutics by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company’s stock worth $1,078,000 after acquiring an additional 931 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Apogee Therapeutics during the fourth quarter worth $43,000. Arizona State Retirement System lifted its holdings in Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after purchasing an additional 960 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in shares of Apogee Therapeutics by 8.9% in the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock valued at $552,000 after purchasing an additional 1,000 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.